Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Alpha Tau Medical Ltd ( (DRTS) ) has shared an update.
On May 8, 2026, Alpha Tau Medical filed a Form 6-K noting a press release about its Alpha DaRT technology and ongoing clinical efforts in difficult-to-treat cancers. The company, listed on Nasdaq under tickers DRTS and DRTSW, continues to position its intratumoral alpha-radiation platform as a targeted option for solid tumors, emphasizing its potential to minimize damage to healthy tissue.
In the May 8, 2026 release, Alpha Tau announced it would host a conference call and webcast on May 11, 2026 to discuss interim data from the first three patients treated in its U.S. REGAIN trial for recurrent glioblastoma. The study plans to enroll up to ten U.S. patients to assess the feasibility and safety of Alpha DaRT in recurrent GBM, a setting with limited options, signaling a key early milestone for stakeholders tracking the therapy’s clinical progress and regulatory trajectory.
The most recent analyst rating on (DRTS) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
Spark’s Take on DRTS Stock
According to Spark, TipRanks’ AI Analyst, DRTS is a Neutral.
The score is held back primarily by very weak financial performance (no revenue, widening losses, and accelerating cash burn), which increases funding and dilution risk. Technicals are more constructive on a longer-term basis (above 50/100/200-day averages with neutral momentum), but valuation is limited by negative earnings and no dividend support.
To see Spark’s full report on DRTS stock, click here.
More about Alpha Tau Medical Ltd
Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company founded in 2016 that focuses on the research, development and potential commercialization of Alpha DaRT, an intratumoral alpha-radiation therapy for solid tumors. The technology, originally developed at Tel Aviv University, aims to deliver highly localized, high-energy alpha particles to destroy tumors while sparing surrounding healthy tissue.
Average Trading Volume: 331,780
Technical Sentiment Signal: Buy
Current Market Cap: $690.9M
Learn more about DRTS stock on TipRanks’ Stock Analysis page.